Funders › MA › Alzheimer's Disease Research Foundation › 2025
Grants paid by Alzheimer's Disease Research Foundation, tax year 2025
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
In tax year 2025, Alzheimer's Disease Research Foundation (EIN 52-2396428) reported 161 grants paid totaling $33,812,354. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2025
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2025 | Massachusetts General Hospital Boston, MA | A | $1,955,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $575,000 | paid | APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $431,250 | paid | A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $402,500 | paid | NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $402,500 | paid | SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES | 202641319349301469 |
| 2025 | University of California Irvine Irvine, CA | A | $402,492 | paid | PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $398,521 | paid | UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $344,528 | paid | NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | The Mclean Hospital Corporation Belmont, MA | A | $327,501 | paid | EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS | 202641319349301469 |
| 2025 | Duke University School of Medicine Durham, NC | A | $320,033 | paid | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202641319349301469 |
| 2025 | National Institute of Neurological Disorders & Stroke Bethesda, MD | A | $287,673 | paid | BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $287,500 | paid | NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD | 202641319349301469 |
| 2025 | Stanford University Redwood City, CA | A | $287,500 | paid | BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? | 202641319349301469 |
| 2025 | University of Rochester Rochester, NY | A | $287,500 | paid | BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $287,500 | paid | NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $287,500 | paid | BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $287,499 | paid | BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of California Irvine Irvine, CA | A | $287,490 | paid | NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS | 202641319349301469 |
| 2025 | Massachusetts Institute of Technology Cambridge, MA | A | $287,477 | paid | BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS | 202641319349301469 |
| 2025 | University of California Davis Davis, CA | A | $286,466 | paid | NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION | 202641319349301469 |
| 2025 | University of Pennsylvania Philadelphia, PA | A | $284,678 | paid | APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY | 202641319349301469 |
| 2025 | University of Alabama at Birmingham Birmingham, AL | A | $271,375 | paid | EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $264,500 | paid | BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $258,750 | paid | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $258,750 | paid | A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $258,750 | paid | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $258,750 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $258,615 | paid | DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $258,573 | paid | DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $252,076 | paid | MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $230,000 | paid | APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $230,000 | paid | MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY | 202641319349301469 |
| 2025 | University of California Irvine Irvine, CA | A | $230,000 | paid | ENGINEERED CAR-MACROPHAGES TO CLEAR TAU | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $230,000 | paid | INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY | 202641319349301469 |
| 2025 | The Broad Institute Inc Cambridge, MA | A | $230,000 | paid | INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $230,000 | paid | UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Texas Southwestern Medical Center Dallas, TX | A | $230,000 | paid | ENGINEERED CAR-MACROPHAGES TO CLEAR TAU | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $228,900 | paid | DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $210,962 | paid | MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Duke University School of Medicine Durham, NC | A | $204,656 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $201,251 | paid | MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $201,250 | paid | ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | ANTIVIRAL CYTOKINE SIGNALING PROMOTES NEURODEGENERATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $201,250 | paid | DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODEL | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | HOW DO MICROGLIA CONTRIBUTE TO THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE? | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | INTERNEURON THERAPY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $201,250 | paid | VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $201,250 | paid | A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | PROBING THE MOLECULAR UNDERPINNINGS OF HOW G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATES PROTECTIVE RESPONSES TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202641319349301469 |
| 2025 | Northwestern University Chicago, IL | A | $201,250 | paid | ROLE OF TAU IN PRESYNAPTIC DYSFUNCTION DURING THE CELLULAR PHASE OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | LINKING SLEEP DYSFUNCTION TO TAU-RELATED DEGENERATION ACROSS AD VARIANTS | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $201,250 | paid | IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL | 202641319349301469 |
| 2025 | Johns Hopkins University Baltimore, MD | A | $201,250 | paid | A TEMPORALLY ALIGNED MULTIMODAL FRAMEWORK FOR INDIVIDUALIZED ALZHEIMER'S DISEASE RISK ASSESSMENT AND DEEP LEARNING-DRIVEN PROGNOSIS | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE 4 GENE ALLELE IN ANIMAL MODELS | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | THE MULTI-OMIC ROADMAP TO NEURONAL SENESCENCE IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ENGINEERING A HUMAN REGION-SPECIFIC SYSTEM TO PROBE APOE-LINKED CELLULAR VULNERABILITY AND RESILIENCE IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CIRCUIT DYNAMICS IN APOE4 MICE | 202641319349301469 |
| 2025 | The Salk Institute for Biological Studies La Jolla, CA | A | $201,250 | paid | THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Mayo Clinic Rochester Rochester, MN | A | $201,250 | paid | BRIDGING THE GAP: SEX-SPECIFIC DRIVERS OF SENESCENCE UNDERLYING NEURODEGENERATION | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CENTENARIAN MICROGLIA REVEAL A NEPRILYSIN-DEPENDENT MECHANISM OF RESILIENCE IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | RIN3 AND BIN1 INTERACTION CONNECTS ENDOSOMAL PATHOLOGY WITH AMYLOID PATHOLOGY | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $201,250 | paid | SON-DEPENDENT NUCLEAR SPECKLE REJUVENATION: A NOVEL PROTEOSTASIS-BASED THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Memorial Sloan Kettering Cancer Center New York, NY | A | $201,250 | paid | DEVELOPMENT AND MECHANISM OF AUTOPHAGY ACTIVATORS FOR TREATMENT OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Augusta University Research Institute Inc Augusta, GA | A | $201,250 | paid | THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | SLEEP REINFORCES HOMEOSTATIC SET-POINTS IN NEURAL ACTIVITY AND MITIGATES NEURODEGENERATIVE DISEASE | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $201,250 | paid | MICROGLIAL MITOCHONDRIAL DYSFUNCTION AND TAU TOXICITY IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | DEVELOPMENT OF A FLAP-TARGETED NEUROIMMUNE PET TRACER FOR IMAGING MICROGLIA IN AD | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $201,250 | paid | MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE-ONSET ALZHEIMER'S DISEASE IN WOMEN | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $201,250 | paid | DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | IDENTIFYING SEX-AWARE X-CHROMOSOME TARGETS FOR PRECLINICAL ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Carnegie Mellon University Pittsburgh, PA | A | $201,250 | paid | INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | ROLE OF PLATELET-DERIVED FACTORS IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY | 202641319349301469 |
| 2025 | Columbia University New York, NY | A | $201,250 | paid | NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | DIGITAL NEUROPATHOLOGY INFRASTRUCTURE FOR PRECISION MEDICINE IN SOUTH TEXAS HISPANIC AD/ADRD POPULATIONS | 202641319349301469 |
| 2025 | Beth Israel Deaconess Medical Center Boston, MA | A | $201,250 | paid | INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of South Florida Tampa, FL | A | $201,250 | paid | BIN1 IN MICROGLIAL HETEROGENEITY ALONG AD PROGRESSION AND MICROGLIAL FUNCTION | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | COGNITIVELY HEALTHY NONAGENARIANS IN THE CROSS COHORT COLLABORATION (CCC) | 202641319349301469 |
| 2025 | Columbia University New York, NY | A | $201,250 | paid | SEMAPHORIN REGULATION OF DISEASE-ASSOCIATED MICROGLIA IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $201,250 | paid | DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Emory University Atlanta, GA | A | $201,250 | paid | MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION | 202641319349301469 |
| 2025 | Johns Hopkins University Baltimore, MD | A | $201,250 | paid | FROM MOLECULAR HETEROGENEITY TO PREDICTIVE MEDICINE: TRANSFORMING NEURODEGENERATIVE DISEASE RESEARCH THROUGH SPATIAL MULTI-OMICS AND INTERPRETABLE AI | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | PRECISION GENE THERAPY TARGETING MICROGLIA IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Northwestern University Chicago, IL | A | $201,250 | paid | SEX-SPECIFIC MECHANISMS OF NEUROINFLAMMATION IN THE ALZHEIMER'S DISEASE HYPOTHALAMUS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | THE JEFFREY L. MORBY PRIZE | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of California Davis Davis, CA | A | $201,250 | paid | DECIPHERING PHOSPHORYLATION-DEPENDENT TAU ENVELOPE DYSFUNCTION TO PREVENT ALZHEIMER'S NEURODEGENERATION | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,235 | paid | RESTORING BRAIN COLLECTION IN NEW YORK CITY THROUGH THE MOUNT SINAI NEUROPATHOLOGY BRAIN BANK | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $201,234 | paid | T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,212 | paid | NEUROPROTECTIVE T CELL-BASED THERAPY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Houston Methodist Research Institute (houston Methodist Hospital Foundation Houston, TX | A | $201,167 | paid | A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS | 202641319349301469 |
| 2025 | University of Massachusetts Chan Medical School Worcester, MA | A | $200,568 | paid | VENTRICULAR EPENDYMAL CELLS: A NOVEL NEURAL-IMMUNE SIGNALING AXIS DURING AGING AND NEURODEGENERATION | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $200,532 | paid | HYPERTENSION, TAU AND NEURODEGENERATION | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $200,530 | paid | MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $200,416 | paid | CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Kentucky Lexington, KY | A | $200,187 | paid | LOWERING MICROGLIAL LIPID BURDEN VIA PLIN2 MODULATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Washington Seattle, WA | A | $200,043 | paid | ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDO-LYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $199,281 | paid | CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER DISEASE PATHOGENESIS | 202641319349301469 |
| 2025 | Stanford University Redwood City, CA | A | $198,370 | paid | OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Stanford University Redwood City, CA | A | $198,253 | paid | BMP LIPID METABOLISM AS A THERAPEUTIC TARGET FOR LYSOSOMAL FUNCTION AND ALZHEIMER'S DISEASE PATHOGENESIS | 202641319349301469 |
| 2025 | University of California Los Angeles Los Angeles, CA | A | $191,463 | paid | NOVEL AI DECODES AGING NEURONS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $182,921 | paid | MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $181,004 | paid | BRIDGING MYELIN AND VASCULAR DEMENTIA: OLIGODENDROCYTE STRESS RESPONSES IN AGEING AND CEREBROVASCULAR DISEASE | 202641319349301469 |
| 2025 | Seattle Neurosound Solutions Seattle, WA | A | $175,000 | paid | CONTINUOUS MONITORING AND ENHANCEMENT OF GLYMPHATIC FLOW IN HUMAN SLEEP | 202641319349301469 |
| 2025 | Burke Neurological Institute White Plains, NY | A | $173,007 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | State of Maryland -University of Maryland Baltimore Baltimore, MD | U | $171,037 | paid | EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $150,937 | paid | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $150,786 | paid | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | 202641319349301469 |
| 2025 | Johns Hopkins University Baltimore, MD | A | $143,697 | paid | BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY | 202641319349301469 |
| 2025 | Baylor College of Medicine Houston, TX | A | $138,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $124,653 | paid | CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $115,000 | paid | CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $103,168 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $100,625 | paid | CHARACTERIZATION AND OPTIMIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS | 202641319349301469 |
| 2025 | University of Pittsburgh Pittsburgh, PA | A | $100,625 | paid | AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Trustees of Tufts College DBA Tufts University Medford, MA | A | $100,625 | paid | ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $100,625 | paid | AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $100,600 | paid | ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $98,083 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY | 202641319349301469 |
| 2025 | St Jude Children's Research Hospital Memphis, TN | A | $92,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | New York Genome Center New York, NY | A | $86,250 | paid | CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $80,500 | paid | MECHANISMS REGULATING NEUROVASCULAR FUNCTION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $80,500 | paid | COMBINATORIAL ROLES OF EED AND PICALM IN MICROGLIAL CLEARANCE PATHWAYS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $80,500 | paid | FBAT-EQUIVALENCE TESTING IN THE PRESENCE OF MODEL UNCERTAINTY FOR THE CURE ALZHEIMERS GENOME PROJECT | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $80,500 | paid | HOW BODY-BRAIN INFLAMMATORY SIGNALS VIA BORDER MACROPHAGES ALTER THE NEUROIMMUNE LANDSCAPE AND DRIVE ALZHEIMER'S PATHOLOGY | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $80,500 | paid | MICROGLIAL-ASTROCYTIC MECHANISMS OF APOE3 CHRISTCHURCH-MEDIATED RESILIENCE TO TAUOPATHY | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $80,500 | paid | ASTROCYTE NETWORK STRUCTURE AND FUNCTION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | National Institute of Neurological Disorders & Stroke Bethesda, MD | A | $80,500 | paid | DYNAMIC INVESTIGATION OF LYMPHATIC PATHWAY INTERCONNECTIONS FOR CEREBROSPINAL FLUID CLEARANCE OF THE HUMAN CENTRAL NERVOUS SYSTEM IN VIVO UNDER PHYSIOLOGICAL CONDITIONS OF THE BRAIN'S BORDERS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $80,500 | paid | SLEEP AUGMENTATION REINFORCES NEURAL COMPUTATION, ENHANCES COGNITION, AND MITIGATES NEURODEGENERATIVE DISEASE SYMPTOMS | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $80,500 | paid | DEFINE ADGRG1-MEDIATED PROTECTIVE MICROGLIAL RESPONSE TO TAU TANGLES IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Kentucky Lexington, KY | A | $78,090 | paid | ASSESSING THE ROLE OF APOE IN GLIAL LIPID DROPLET METABOLISM AND FUNCTION | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $77,709 | paid | SUPPRESSING NEUROINFLAMMATION WITH A TARGETED PROTEIN DEGRADATION STRATEGY IN A TAUOPATHY MOUSE MODEL | 202641319349301469 |
| 2025 | University of Southern California Los Angeles, CA | A | $57,500 | paid | NEURAL STEM CELL REJUVENATION FOR SYMPTOMATIC ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Houston Methodist Research Institute (houston Methodist Hospital Foundation Houston, TX | A | $57,500 | paid | CANCER-DERIVED EXTRACELLULAR VESICLE MICRORNAS AS SYSTEMIC MODULATORS OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $57,500 | paid | TRACKING INFLAMMATION AND REPAIR AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Maryland Medical Legal Foundation Baltimore, MD | A | $57,500 | paid | BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY | 202641319349301469 |
| 2025 | Northwestern University Chicago, IL | A | $57,500 | paid | ROLE OF ANNEXIN A6-MEDIATED MEMBRANE REPAIR IN ALZHEIMER'S PATHOLOGY | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $50,312 | paid | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $38,944 | paid | PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA (SUPPLEMENT) | 202641319349301469 |
| 2025 | University of Miami Atlanta, GA | A | $24,589 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts Institute of Technology Cambridge, MA | A | $9,752 | paid | DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE (SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $8,533 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $4,025 | paid | ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS (SUPPLEMENT) | 202641319349301469 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.